March 26, 2025
J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca’s Tagrisso
Continuance of life, Combined, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Overall Survival, Tagrisso
Senate confirms Johns Hopkins surgeon Marty Makary to lead FDA amid turbulence at the agency
Makary, Senate, United States Food and Drug Administration, Surgeon, Johns, Agencies, Dr., Marty
AI-Powered Drug Discovery Breakthrough: Charles River and Valo Health Identify Lupus Candidate
Charles River Laboratories, Valo Health, Logica platform, AI-driven drug discovery, lupus treatment, Pioneering Medicines, Flagship Pioneering
Eisai Revises Leqembi Sales Forecast for 2027, Remains Optimistic About Growth
Leqembi, Alzheimer’s disease, sales forecast, Eisai, Biogen, revenue projection
Epicrispr raises $68M, will start clinical trial of epigenetic editing for FSHD
Muscular Dystrophy, Facioscapulohumeral, Epicrispr, Clinical Trials, EPI-321
GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?
Glucagon-Like Peptide 1, Industry, Market, Effectiveness, Oral cavity, production, injectables, Orals, orforglipron, Manufacture, GLP-1s
BioSpace Presents the World Atlas of GLP-1s
Eli Lilly, Wegovy, India, China, BioSpace, World, Cervical Atlas, GLP-1s, Nordisk, Glucagon-Like Peptide 1, Brazil, India
Hillstar Bio Launches with $67M to Develop Precision Immunotherapies for Autoimmune Diseases
Precision immunology, autoimmune diseases, TRBV9+ T cells, axial spondyloarthritis, Series A funding
Merck Acquires Rights to Hengrui’s Oral Lp(a) Inhibitor in $2B Deal
Merck, Hengrui Pharmaceuticals, HRS-5346, Lp(a) inhibitor, cardiovascular disease, atherosclerosis, licensing agreement